國立虎尾科技大學 |

Small Molecules in Oncology

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Small Molecules in Oncology/ edited by Uwe M. Martens.
other author:	Martens, Uwe M.
Description:	VIII, 276 p. 34 illus., 19 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-3-319-91442-8
ISBN:	9783319914428

Small Molecules in Oncology
Small Molecules in Oncology[electronic resource] /edited by Uwe M. Martens. - 3rd ed. 2018. - VIII, 276 p. 34 illus., 19 illus. in color.online resource. - Recent Results in Cancer Research,2110080-0015 ;. - Recent Results in Cancer Research,200.

Erlotinib -- Lapatinib -- Sorafenib -- Regorafenib -- Crizotinib -- Cabozantinib -- Vemurafenib -- Trametinib -- Everolimus -- Vismodegib -- Larotrectinib -- Palbociclib -- Taselisib -- Cobimetinib -- Lenvatinib -- Afatinib -- Olaparib -- Gefitinib -- Ceritinib. .

This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology. .

ISBN: 9783319914428

Standard No.: 10.1007/978-3-319-91442-8doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Small Molecules in Oncology
LDR:02790nam a22004095i 4500 001 987815
003 DE-He213
005 20200702165748.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319914428 $9 978-3-319-91442-8
024 7 $a 10.1007/978-3-319-91442-8 $2 doi
035 $a 978-3-319-91442-8
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Small Molecules in Oncology $h [electronic resource] / $c edited by Uwe M. Martens.
250 $a 3rd ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a VIII, 276 p. 34 illus., 19 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 211
505 0 $a Erlotinib -- Lapatinib -- Sorafenib -- Regorafenib -- Crizotinib -- Cabozantinib -- Vemurafenib -- Trametinib -- Everolimus -- Vismodegib -- Larotrectinib -- Palbociclib -- Taselisib -- Cobimetinib -- Lenvatinib -- Afatinib -- Olaparib -- Gefitinib -- Ceritinib. .
520 $a This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology. .
650 0 $a Oncology . $3 1253469
650 0 $a Cancer research. $3 1253664
650 1 4 $a Oncology. $3 593951
650 2 4 $a Cancer Research. $3 668358
700 1 $a Martens, Uwe M. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1207758
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319914411
776 0 8 $i Printed edition: $z 9783319914435
776 0 8 $i Printed edition: $z 9783030082574
830 0 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 200 $3 1263334
856 4 0 $u https://doi.org/10.1007/978-3-319-91442-8
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)